Conjugated linoleic acid is related to bone mineral density but does not affect parathyroid hormone in men

详细信息    查看全文

• 作者：Jason R. DeGuire^a ; Nour Makarem^a ; Catherine A. Vanstone^a ; Suzanne Morin^b ; Gustavo Duque^c ; Hope A. Weiler^a ; ^{hope.weiler@mcgill.ca}
• 关键词：1.5CLA ; 1.5 g/d c9 ; t11 CLA ; 25(OH)D ; 25-hydroxyvitamin D ; 3.0CLA ; 3.0 g/d c9 ; t11 CLA ; BAP ; bone-specific alkaline phosphatase ; BMC ; bone mineral content ; BMD ; bone mineral density ; BMI ; body mass index ; c9 ; t11 ; cis-9 ; trans-11 CLA isomer ; CLA ; conjugat
• 刊名：Nutrition Research
• 出版年：2012
• 出版时间：December, 2012
• 年：2012
• 卷：32
• 期：12
• 页码：911-920
• 全文大小：676 K

文摘

The relationships between conjugated linoleic acid (CLA) status, bone, body composition, and the effect of CLA on calciotropic hormones are unclear. A cross-sectional study was designed to examine the association between c9, t11 CLA status in erythrocyte membranes (RBC) and body composition. This preceded a dose-response trial investigating if c9, t11 CLA affected parathyroid hormone (PTH). It was hypothesized that (1) higher c9, t11 CLA status in RBC will be associated with a lower fat and higher bone mass and that (2) PTH will be reduced by 30 % after supplementation of c9, t11 CLA. Fifty-four men (age, 19-53 years) were included in the cross-sectional analysis, of which 31 were studied in the dose-response trial and randomized to 1 of 3 groups: placebo (n = 10), 1.5 g/d (n = 11), or 3.0 g/d (n = 10) of c9, t11 CLA for 16 weeks. Men with RBC c9, t11 CLA status above the median had higher whole body bone mineral density (BMD) (1.359 ¡À 0.024 vs 1.287 ¡À 0.023 g/cm²; P = .04) and whole body lean mass (WBL) percentage (78.8 % ¡À 0.9 % vs 75.3 % ¡À 1.0 % ; P = .01), whereas body mass index (24.8 ¡À 0.5 kg/m² vs 27.3 ¡À 0.9 kg/m²; P = .01) and whole body fat mass percentage (17.3 % ¡À 0.9 % vs 21.3 % ¡À 1.1 % ; P = .007) were lower. In regression analysis, RBC c9, t11 CLA status accounted for a significant proportion (r² = 0.10) of the variation in whole body BMD (P = .03). There were no time or treatment differences among any bone or biomarkers of bone metabolism including PTH. These findings indicate that RBC c9, t11 CLA status, a reflection of long-term (~4 months) dietary CLA intake, positively relates to BMD. However, c9, t11 CLA supplementation does not appear to affect PTH in healthy men.